BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LY3954068 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LY3954068\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06297590-696@assetmemo.bio
DTSTAMP:20261121T005859Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:LY3954068: Phase 1 readout est. (NCT06297590)
DESCRIPTION:LY3954068\, phase 1\, Alzheimer's Disease.\nStudy: A First-In-H
 uman Study of LY3954068 in Participants With Early Symptomatic Alzheimer's
  Disease\nEstimated primary completion: July 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ly3954068#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06297590
URL:https://assetmemo.bio/drug/ly3954068#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
